Of the 1262 participants, 208 were categorized as having a definite indication to start HAART (Group A), including 99 (48%) due to a CD4 count below 200 cells/mm3, 99 (48%) due to severe symptoms, and 10 (5%) for an AIDS-defining condition. This evidence concerns the gene CD4 and AIDS.